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IN VITRO KNOCKDOWN OF SOX9 AFFECTS CELL SURVIVAL VIA P21
AND CYCLIN D1 AND FAVORS OSTEOGENIC DIFFERENTIATION OF MSC
S. Stoeckl1,2, A. Bosserhoff3, C. Go¨ttl1,2, J. Grifka2, S. Gra¨ssel1,2. 1Ctr.
for Med. Biotechnology, Regensburg, Germany; 2Orthopaedic Surgery,
Experimental Orthopaedics, Regensburg, Germany; 3Dept. of Pathology,
Regensburg, Germany
Purpose: The transcription factor Sox9 regulates skeletal growth and
cartilage formation in mesenchymal stem cells and osteochondro-
progenitor cells which can differentiate towards chondrocytes or
osteoblasts. Sox9 is absent in hypertrophic chondrocytes where a
misexpression in vivo causes lack of bone marrow, inhibition of cartilage
resorption and failure of vascular invasion in mice. Moreover, there is
evidence that Sox9 is related to more biological processes than only to
osteo-chondrogenesis, for example cell cycle regulation or tumourigenic
development. The aim of our study is to determine the role of Sox9 in
undifferentiated rat mesenchymal stem cells (rMSC) in cell survival and
its impact on osteogenic differentiation capacity.
Methods: Mesenchymal stem cells (rMSC), isolated from bone-marrow
and adipose tissue of 6 week old rats, were transduced with a retroviral
vector containing a Sox9-speciﬁc shRNA or the Sox9 cDNA sequence for
either generating an in vitro gene knockdown or an overexpression of
Sox9. The Sox9 level was determined with quantitative real-time PCR
(qPCR) on mRNA level and with western blotting and luciferase-reporter
assays on protein level. The effects of the altered Sox9 dose on selected
marker genes were investigated by qPCR, ELISA and western blotting.
Proliferation was quantiﬁed with a BrdU – ELISA, cell cycle distribution
was analysed with FACS and apoptotic activity with a caspase 3/7 assay.
For transduced cells, subjected to osteogenic differentiation for up to
21 days, osteogenic marker gene expression was analyzed via qRT-PCR
and osteogenic differentiation status was investigated with alizarin red
staining.
Results: A reproducible Sox9 knockdown between 50% and 90% and
a 10 to 100 fold overexpression of Sox9 was generated in both, bone
marrow (BM) and adipose tissue derived (AD) MSC. Downstream effects
of Sox9 silencing are a signiﬁcant down regulation of Integrin alpha 11,
Mmp13 and Bcl-2 gene expression in BM-MSC, whereas Osteocalcin is
up regulated in BM-MSC and in AD-MSC. Overexpressing Sox9 results
in opposite regulation of gene expression in rBM-MSC. The BrdU assay,
measurement of cell doubling time and cell cycle analysis via FACS
displays a reduction of proliferation after Sox9 knockdown and a
reduced G1 to S-phase transition rate. A caspase 3/7 assay indicates
an increase in apoptotic activity. The protein amount of p21 and Cyclin
D1, analyzed via western blotting, was clearly increased after Sox9
inhibition. Furthermore, osteogenic differentiation studies demonstrate
an upregulation of Runx2, Mmp13, Vegfa and Osteocalcin in Sox9
knockdown cells after 14 days of osteogenesis, whereas Msx2 and Dlx5
expression is diminished.
Conclusions: Based on these studies, we conclude a negative effect
of Sox9 on apoptosis, and a positive effect on cell proliferation and
cell viability. Alterations of Bcl2, p21 and Cyclin D1 protein expression
after Sox9 reduction point to an important role of Sox9 in cell survival
and cell cycle control in MSC. Possibly, Sox9 modulates transcriptional
activation of inhibitors of p21 and Cyclin D1 or induce phosphorylation
through speciﬁc kinases and consequently their degradation. Our ﬁndings
furthermore indicate an acceleration of osteogenic differentiation due to
inhibition of Sox9, mainly during early osteogenesis of MSC. A possible
mechanism for that effect is a direct or indirect interaction of Sox9 with
one of the major transcription (co) factors in early osteogenesis like
Runx2, Msx2 or Dlx3, three key players of Osteocalcin expression, which
all contain at least one potential Sox9 binding site within their promoter
region.
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FIBROBLAST GROWTH FACTORS 18 AND 9 REGULATE CHONDROGENIC
DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS
D. Correa1, E. Rom2, J.F. Welter1, L. Duesler1, A. Yayon2, A.I. Caplan1.
1Case Western Reserve Univ., Cleveland, OH, USA; 2ProCore Ltd., Ness Ziona,
Israel
Purpose: FGF18 is currently in clinical trials for repair of acute cartilage
injury of the knee and in patients with osteoarthritis. Little is known
about the role of FGF9 in cartilage biology. This work, therefore, aims to
elucidate the effect of these two FGF family members at different stages
of the in vitro chondrogenic differentiation program of hMSCs, and the
relationship between them and the known mitogenic/pro-chondrogenic
effects of FGF2.
Methods: Cell proliferation: coverslip-cultured hMSCs were stimulated
for 72h with 10ng/ml rhFGF2, rhFGF18 or rhFGF9, followed by BrdU
immunostaining. Chondrogenic induction: control and FGF2-expanded
cells were cultured in aggregates with (complete chondrogenic medium)
and without (deﬁned medium) TGF-b in the presence of 10ng/ml
rhFGF18 or rhFGF9 and mutant ligands that exclusively signal through
FGFR3 (FGF18v3 and FGF9v1), starting at different times of the
chondroinductive program. qRT-PCR and immunocytochemistry (ICC)
was performed at days 0 (right after expansion) and 3, followed by
histological/biochemical analysis after 3 weeks. Hypertrophy delay: the
aggregate cultures were switched after 2 weeks to a hypertrophy-
inducing medium (TGF-b withdrawal, low Dexamethasone, 1 ng/ml
Triiodothyronine) for 2 additional weeks, along with rhFGF18, rhFGF9,
FGF18v3, FGF9v1, and neutralizing antibodies against FGFR1 and FGFR3.
Histological/biochemical analysis and Alkaline Phosphatase (ALP) activity
assessment as a marker of hypertrophy-induced changes were then
performed.
Results: Cell proliferation: compared with control (24% BrdU-positive
cells), the mitogenic effect of FGF2 was conﬁrmed (46%), while FGF18 had
no effect (29%) and FGF9 a negative one (15%). Chondrogenic induction:
in FGF2-expanded cells Sox9 was upregulated on day 0, suggesting that
the chondrogenic regulatory machinery is activated earlier by FGF2. By
ICC, Sox9 and BrdU expression did not coincide, suggesting that there
are at least two subpopulations which respond differently to FGF2. FGF2
expansion upregulated FGFR2 and FGFR3, while it downregulated FGFR1,
evident after three days in aggregate culture with complete chondrogenic
medium. FGF18, FGF9 and the mutant ligands (in deﬁned medium)
partially replaced TGF-b chondrogenic induction in control-expanded
cells, while they inhibited differentiation of FGF2-expanded cells. This
suggests that FGFR1 (FGF2) and FGFR2/3 (FGF18/9) signaling antagonize
each other, or that these ligands were at “toxic” concentrations, given the
upregulated receptor expression generated by FGF2 expansion. FGF18
had an anabolic effect on top of TGF-b when added early (d0). This
effect was dissipated when it was administered later (d7 and d14). The
effect is mediated by FGFR3, as FGF18v3 recapitulated the same effect.
These ligands also had a negative effect on chondrogenesis of FGF2-
expanded cells, when administered along with TGF-b, regardless of the
time of administration. Hypertrophy delay: FGF18 and FGF9 delay, mainly
through FGFR3 signaling, the appearance of the induced hypertrophy-
related changes in cell size and ALP activity. Additionally, they still exert a
signiﬁcant anabolic effect (FGF9) even under these special pro-terminally
differentiating conditions.
Conclusions: The 3 factors exhibit important effects at all stages of
hMSC chondrogenesis. FGF2 expands them, and shifts the chondrogenic
program earlier, by upregulating Sox9 expression. FGF18/9, signaling
primarily through FGFR3, partially replaces TGF-b, have anabolic
properties, and delay the appearance of changes related to hypertrophic
differentiation. However, they have a negative impact on FGF2-expanded
cells, which requires further research in order to be able to synergize
their individual positive effects. Collectively, these factors could be used
to optimize the pre-implantation culture conditions of hMSCs when used
as part of engineered cartilage grafts.
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GSK-3ALPHA AND GSK-3BETA MODULATE EARLY STAGES OF
CHONDROCYTE DIFFERENTIATION THROUGH PHOSPHORYLATION
OF RELA/NF-KAPPAB P65
S. Itoh, T. Saito, M. Hirata, M. Ushita, T. Ikeda, K. Nakamura, U-i. Chung,
H. Kawaguchi. Sensory & Motor System Med., Univ. of Tokyo, Tokyo, Japan
Purpose: Glycogen synthase kinase-3 (GSK-3) is a serine/threonine
kinase that phosphorylates various substrates to mediate principal
signals in many cells. Here we have examined individual roles of the
two mammalian isoforms, GSK-3a and GSK-3b, in chondrocytes.
Methods: Chondrocyte differentiation was determined by the mRNA
and protein levels of early differentiation markers (Sox9, Col2a1, and
aggrecan) and late differentiation markers (Col10a1, Indian hedgehog,
and Pth1r). In vitro expression patterns were examined in cultures
of mouse chondrogenic ATDC5 cells with the differentiation medium
(insulin, transferrin, and sodium selenite) and primary chondrocytes
isolated from the ribs of mouse embryos. In vivo expression patterns
